evolocumab: Clinical Trials

41 trials of evolocumab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

36 completed, 2 terminated, 1 active not recruiting, 1 not yet recruiting. 41 Phase 3, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 341Completed 36, Terminated 2, Active not recruiting 1, Not yet recruiting 1, Unknown 1
Phase 23Completed 2, Not yet recruiting 1

Follow evolocumab: new trials by email Literature Review of evolocumab trials Research Report on evolocumab

Trials (filtered) newest first · largest first

All 41 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
PCSK9 Inhibitors in Acute Ischemic Stroke Patients Undergoing Endovascular Therapy
PCSK9 inhibitor - Acute Ischemic Stroke
Phase 2 / Phase 3Not yet recruitingNanfang Hospital, Southern Medical University4782025-09-152025-09-15
Evolocumab Added to Statin Therapy in Symptomatic Intracranial Atherosclerotic Stenosis (EAST-ICAS)
Evolocumab, Atorvastatin - Stroke Patients With Symptomatic Intracranial Atherosclerotic Stenosis
Phase 3UnknownThe First Affiliated Hospital with Nanjing Medical University802023-04-152023-06-02
Impact of PCSK9 Inhibition on Clinical Outcome in Patients During the Inflammatory Stage of the COVID-19
Evolocumab, Saline solution - Sars-CoV-2 Infection
Phase 3CompletedCollegium Medicum w Bydgoszczy602021-06-012023-04-21
Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients
lerodalcibep, evolocumab, alirocumab - Hypercholesterolemia, Cardiovascular Diseases
Phase 3CompletedLIB Therapeutics LLC2042021-04-222023-03-29
Evolocumab in STEMI
Repatha® - ST Elevation Myocardial Infarction
Phase 3Active not recruitingSejong General Hospital1662020-12-052025-06-19
Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH
lerodalcibep, evolocumab - Homozygous Familial Hypercholesterolemia
Phase 3CompletedLIB Therapeutics LLC652019-12-072023-03-29
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
Evolocumab, Placebo - Coronary Heart Disease (CHD)
Phase 3CompletedAmgen123012019-06-112026-06-25
Cholesterol Lowering With EVOLocumab to Prevent Cardiac Allograft Vasculopathy in De-novo Heart Transplant Recipients
Evolocumab, Placebo - Cardiac Allograft Vasculopathy
Phase 3CompletedLars Gullestad1302019-06-102023-11-01
Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia
evolocumab, placebo - Primary Hypercholesterolemia, Mixed Dyslipidemia
Phase 3TerminatedAmgen2592019-05-092023-03-27
Effect of Evolocumab on Coronary Atherosclerosis
Evolocumab, 18F-NaF PET, CCTA - Cardiovascular Disease, Hyperlipidemia
Phase 3CompletedCedars-Sinai Medical Center552019-03-192024-07-17
Imaging of Coronary Plaques in Participants Treated With Evolocumab
Evolocumab, Placebo, Statin therapy - Coronary Artery Disease (CAD)
Phase 3CompletedAmgen1642018-11-192022-05-03
PCSK 9 Inhibition as Secondary Prevention in Renal Transplant Patients
Evolocumab - Kideny Transplant Recipients With High Cardiovascular Risk Score
Phase 3CompletedHamid Al-Essa Organ Transplant Center2002018-05-012020-12-14
EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS)
Evolocumab 140 mg/mL, Placebo - Acute Coronary Syndrome
Phase 3CompletedInsel Gruppe AG, University Hospital Bern3082018-01-232019-08-14
Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia
Evolocumab, Placebo - Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection
Phase 3CompletedAmgen4672017-05-222022-07-22
Evolocumab Versus LDL Apheresis in Patients With Hypercholesterolemia
evolocumab, evolocumab and LDL apheresis, LDL apheresis - Hypercholesterolemia
Phase 3CompletedHospital General Universitario Gregorio Marañon92017-04-012018-02-12
Fourier Open-label Extension Study in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries
Evolocumab - Dyslipidemia
Phase 3TerminatedAmgen16002017-03-132024-05-29
Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia)
Evolocumab - Familial Hypercholesterolemia
Phase 3CompletedAmgen1632016-09-102024-05-29
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension
Evolocumab - Dyslipidemia
Phase 3CompletedAmgen50352016-09-022023-04-07
Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia
Evolocumab, Placebo to Evolocumab - Hypercholesterolemia, Mixed Dyslipidemia
Phase 3CompletedAmgen4242016-05-172018-08-31
Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia
Evolocumab, Atorvastatin, Placebo - Diabetes, Hyperlipidemia, Mixed Dyslipidemia
Phase 3CompletedAmgen9862016-04-142019-01-11

Showing 20 of 41. Sign in to see all of them.

Conditions studied

Hypercholesterolemia (26)  ·  Hyperlipidemias (12)  ·  Dyslipidemias (7)  ·  Homozygous Familial Hypercholesterolemia (4)  ·  Hyperlipoproteinemia Type II (4)  ·  Cardiovascular Diseases (2)  ·  Diabetes Mellitus (2)  ·  Hypercholesterolemia, Autosomal Dominant, 3 (2)  ·  Inhibition, Psychological (2)  ·  Acute Coronary Syndrome (1)  ·  COVID-19 (1)  ·  Coronary Artery Disease (1)  ·  Coronary Disease (1)  ·  Diabetes Mellitus, Type 2 (1)  ·  HIV Infections (1)

Sponsors

Amgen (30)  ·  LIB Therapeutics LLC (2)  ·  Cedars-Sinai Medical Center (1)  ·  Collegium Medicum w Bydgoszczy (1)  ·  Hamid Al-Essa Organ Transplant Center (1)  ·  Hospital General Universitario Gregorio Marañon (1)  ·  Insel Gruppe AG, University Hospital Bern (1)  ·  Lars Gullestad (1)  ·  Nanfang Hospital, Southern Medical University (1)  ·  Sejong General Hospital (1)  ·  The First Affiliated Hospital with Nanjing Medical University (1)

Countries

United States (28)  ·  Canada (22)  ·  Australia (19)  ·  Belgium (17)  ·  France (17)  ·  Italy (17)  ·  South Africa (17)  ·  Spain (17)  ·  Czechia (16)  ·  Netherlands (16)  ·  United Kingdom (15)  ·  Germany (13)  ·  Poland (13)  ·  Denmark (12)  ·  Hungary (12)

Top investigators

Evan A Stein, MD PhD (2)  ·  Daniel S. Berman, MD (1)  ·  Eliano Navarese, Md, PhD (1)  ·  Hua Lu, MD (1)  ·  Jacek Kubica, MD, PhD (1)  ·  Konstantinos Koskinas, MD (1)  ·  Lars Gullestad, MD, PhD (1)  ·  Marian Goicoechea, MD, PhD (1)  ·  Stephan Windecker, Prof., MD (1)

Results publications

PMID 33078867, PMID 24014831, PMID 11277825, PMID 16226162, PMID 25282520, PMID 25773607, PMID 26578202, PMID 26999484, PMID 27039291, PMID 27066336, PMID 27264224, PMID 28304224, PMID 28477848, PMID 28844508, PMID 28859947, PMID 28927706, PMID 29066265, PMID 29133605, PMID 29530884, PMID 29626068, PMID 29898218, PMID 30540337, PMID 30586750, PMID 30851062, PMID 30897995, PMID 30953107, PMID 31116355, PMID 31196453, PMID 31479722, PMID 31748467, PMID 32268367, PMID 32312223, PMID 32318641, PMID 32347885, PMID 32347887, PMID 32393252, PMID 32432684, PMID 32445429, PMID 32785614, PMID 33197560, PMID 33980763, PMID 34537830, PMID 35209731, PMID 35431172, PMID 36007987, PMID 36435949, PMID 36585131, PMID 36653090, PMID 36779348, PMID 38934968

NIH funding

2015 (6), 2014 (3), 2017 (3), 2016 (1), 2018 (1), 2023 (1)